ID CD3D_HUMAN Reviewed; 171 AA. AC P04234; A8MVP6; DT 20-MAR-1987, integrated into UniProtKB/Swiss-Prot. DT 20-MAR-1987, sequence version 1. DT 24-JAN-2024, entry version 220. DE RecName: Full=T-cell surface glycoprotein CD3 delta chain; DE AltName: Full=T-cell receptor T3 delta chain; DE AltName: CD_antigen=CD3d; DE Flags: Precursor; GN Name=CD3D; Synonyms=T3D; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=2939461; DOI=10.1073/pnas.83.9.2944; RA van den Elsen P., Georgopoulos K., Shepley B.-A., Orkin S., Terhorst C.; RT "Exon/intron organization of the genes coding for the delta chains of the RT human and murine T-cell receptor/T3 complex."; RL Proc. Natl. Acad. Sci. U.S.A. 83:2944-2948(1986). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=6095101; DOI=10.1038/312413a0; RA van den Elsen P., Shepley B.-A., Borst J., Coligan J.E., Markham A.F., RA Orkin S., Terhorst C.; RT "Isolation of cDNA clones encoding the 20K T3 glycoprotein of human T-cell RT receptor complex."; RL Nature 312:413-418(1984). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=3488209; DOI=10.1002/j.1460-2075.1986.tb04353.x; RA Tunnacliffe A., Sims J.E., Rabbitts T.H.; RT "T3 delta pre-mRNA is transcribed from a non-TATA promoter and is RT alternatively spliced in human T cells."; RL EMBO J. 5:1245-1252(1986). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RX PubMed=15028279; DOI=10.1016/j.ygeno.2003.09.023; RA Jin P., Fu G.K., Wilson A.D., Yang J., Chien D., Hawkins P.R., Au-Young J., RA Stuve L.L.; RT "PCR isolation and cloning of novel splice variant mRNAs from known drug RT target genes."; RL Genomics 83:566-571(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16554811; DOI=10.1038/nature04632; RA Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K., RA Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T., RA Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G., RA Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C., RA Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A., RA Hattori M., Rogers J., Lander E.S., Sakaki Y.; RT "Human chromosome 11 DNA sequence and analysis including novel gene RT identification."; RL Nature 440:497-500(2006). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Blood; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP PROTEIN SEQUENCE OF 128-171. RX PubMed=2540970; DOI=10.1111/j.1432-1033.1989.tb14693.x; RA Alexander D., Goris J., Marais R., Rothbard J., Merlevede W., RA Crumpton M.J.; RT "Dephosphorylation of the human T lymphocyte CD3 antigen."; RL Eur. J. Biochem. 181:55-65(1989). RN [8] RP FUNCTION, AND PHOSPHORYLATION BY LCK. RX PubMed=2470098; DOI=10.1073/pnas.86.9.3277; RA Barber E.K., Dasgupta J.D., Schlossman S.F., Trevillyan J.M., Rudd C.E.; RT "The CD4 and CD8 antigens are coupled to a protein-tyrosine kinase (p56lck) RT that phosphorylates the CD3 complex."; RL Proc. Natl. Acad. Sci. U.S.A. 86:3277-3281(1989). RN [9] RP SUBUNIT. RX PubMed=1828760; DOI=10.1002/j.1460-2075.1991.tb07687.x; RA Manolios N., Letourneur F., Bonifacino J.S., Klausner R.D.; RT "Pairwise, cooperative and inhibitory interactions describe the assembly RT and probable structure of the T-cell antigen receptor."; RL EMBO J. 10:1643-1651(1991). RN [10] RP INTERACTION WITH CD4 AND CD8. RX PubMed=1396954; DOI=10.1002/eji.1830221002; RA Suzuki S., Kupsch J., Eichmann K., Saizawa M.K.; RT "Biochemical evidence of the physical association of the majority of CD3 RT delta chains with the accessory/co-receptor molecules CD4 and CD8 on RT nonactivated T lymphocytes."; RL Eur. J. Immunol. 22:2475-2479(1992). RN [11] RP TISSUE SPECIFICITY. RX PubMed=1372642; DOI=10.1084/jem.175.4.1055; RA Phillips J.H., Hori T., Nagler A., Bhat N., Spits H., Lanier L.L.; RT "Ontogeny of human natural killer (NK) cells: fetal NK cells mediate RT cytolytic function and express cytoplasmic CD3 epsilon,delta proteins."; RL J. Exp. Med. 175:1055-1066(1992). RN [12] RP FUNCTION, AND SUBUNIT. RX PubMed=12507424; DOI=10.1016/s0092-8674(02)01194-7; RA Call M.E., Pyrdol J., Wiedmann M., Wucherpfennig K.W.; RT "The organizing principle in the formation of the T cell receptor-CD3 RT complex."; RL Cell 111:967-979(2002). RN [13] RP FUNCTION, AND INTERACTION WITH CD8. RX PubMed=12215456; DOI=10.1074/jbc.m208119200; RA Doucey M.A., Goffin L., Naeher D., Michielin O., Baumgaertner P., RA Guillaume P., Palmer E., Luescher I.F.; RT "CD3 delta establishes a functional link between the T cell receptor and RT CD8."; RL J. Biol. Chem. 278:3257-3264(2003). RN [14] RP INVOLVEMENT IN IMD19. RX PubMed=14602880; DOI=10.1056/nejmoa031178; RA Dadi H.K., Simon A.J., Roifman C.M.; RT "Effect of CD3delta deficiency on maturation of alpha/beta and gamma/delta RT T-cell lineages in severe combined immunodeficiency."; RL N. Engl. J. Med. 349:1821-1828(2003). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-149, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=12522270; DOI=10.1073/pnas.2436191100; RA Salomon A.R., Ficarro S.B., Brill L.M., Brinker A., Phung Q.T., Ericson C., RA Sauer K., Brock A., Horn D.M., Schultz P.G., Peters E.C.; RT "Profiling of tyrosine phosphorylation pathways in human cells using mass RT spectrometry."; RL Proc. Natl. Acad. Sci. U.S.A. 100:443-448(2003). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-149, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=15144186; DOI=10.1021/ac035352d; RA Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M., RA Peters E.C.; RT "Robust phosphoproteomic profiling of tyrosine phosphorylation sites from RT human T cells using immobilized metal affinity chromatography and tandem RT mass spectrometry."; RL Anal. Chem. 76:2763-2772(2004). RN [17] RP INVOLVEMENT IN IMD19. RX PubMed=15546002; DOI=10.1172/jci22588; RA de Saint Basile G., Geissmann F., Flori E., Uring-Lambert B., Soudais C., RA Cavazzana-Calvo M., Durandy A., Jabado N., Fischer A., Le Deist F.; RT "Severe combined immunodeficiency caused by deficiency in either the delta RT or the epsilon subunit of CD3."; RL J. Clin. Invest. 114:1512-1517(2004). RN [18] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-160, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [19] RP INVOLVEMENT IN IMD19. RX PubMed=21883749; DOI=10.1111/j.1399-3046.2011.01563.x; RA Yu G.P., Nadeau K.C., Berk D.R., de Saint Basile G., Lambert N., RA Knapnougel P., Roberts J., Kavanau K., Dunn E., Stiehm E.R., Lewis D.B., RA Umetsu D.T., Puck J.M., Cowan M.J.; RT "Genotype, phenotype, and outcomes of nine patients with T-B+NK+ SCID."; RL Pediatr. Transplant. 15:733-741(2011). RN [20] RP X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 23-100 IN COMPLEX WITH CD3E AND RP ANTIBODY FRAGMENT, SUBUNIT, AND DISULFIDE BOND. RX PubMed=15534202; DOI=10.1073/pnas.0407359101; RA Arnett K.L., Harrison S.C., Wiley D.C.; RT "Crystal structure of a human CD3-epsilon/delta dimer in complex with a RT UCHT1 single-chain antibody fragment."; RL Proc. Natl. Acad. Sci. U.S.A. 101:16268-16273(2004). CC -!- FUNCTION: Part of the TCR-CD3 complex present on T-lymphocyte cell CC surface that plays an essential role in adaptive immune response. When CC antigen presenting cells (APCs) activate T-cell receptor (TCR), TCR- CC mediated signals are transmitted across the cell membrane by the CD3 CC chains CD3D, CD3E, CD3G and CD3Z. All CD3 chains contain immunoreceptor CC tyrosine-based activation motifs (ITAMs) in their cytoplasmic domain. CC Upon TCR engagement, these motifs become phosphorylated by Src family CC protein tyrosine kinases LCK and FYN, resulting in the activation of CC downstream signaling pathways (PubMed:2470098). In addition of this CC role of signal transduction in T-cell activation, CD3D plays an CC essential role in thymocyte differentiation. Indeed, participates in CC correct intracellular TCR-CD3 complex assembly and surface expression. CC In absence of a functional TCR-CD3 complex, thymocytes are unable to CC differentiate properly. Interacts with CD4 and CD8 and thus serves to CC establish a functional link between the TCR and coreceptors CD4 and CC CD8, which is needed for activation and positive selection of CD4 or CC CD8 T-cells(PubMed:12215456). {ECO:0000269|PubMed:12215456, CC ECO:0000269|PubMed:12507424, ECO:0000269|PubMed:2470098}. CC -!- SUBUNIT: The TCR-CD3 complex is composed of a CD3D/CD3E and a CD3G/CD3E CC heterodimers that preferentially associate with TCRalpha and TCRbeta, CC respectively, to form TCRalpha/CD3E/CD3G and TCRbeta/CD3G/CD3E trimers. CC In turn, the hexamer interacts with CD3Z homodimer to form the TCR-CD3 CC complex. Alternatively, TCRalpha and TCRbeta can be replaced by CC TCRgamma and TCRdelta. Interacts with coreceptors CD4 and CD8 CC (PubMed:1396954, PubMed:12215456). {ECO:0000269|PubMed:12215456, CC ECO:0000269|PubMed:12507424, ECO:0000269|PubMed:1396954, CC ECO:0000269|PubMed:15534202, ECO:0000269|PubMed:1828760}. CC -!- INTERACTION: CC P04234; Q96EQ0: SGTB; NbExp=3; IntAct=EBI-3862416, EBI-744081; CC -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane CC protein. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P04234-1; Sequence=Displayed; CC Name=2; CC IsoId=P04234-2; Sequence=VSP_045800; CC -!- TISSUE SPECIFICITY: CD3D is mostly present on T-lymphocytes with its CC TCR-CD3 partners. Present also in fetal NK-cells. CC {ECO:0000269|PubMed:1372642}. CC -!- PTM: Phosphorylated on Tyr residues after T-cell receptor triggering by CC LCK in association with CD4/CD8. {ECO:0000269|PubMed:2470098}. CC -!- DISEASE: Immunodeficiency 19 (IMD19) [MIM:615617]: An autosomal CC recessive form of severe combined immunodeficiency characterized by CC onset in early infancy of recurrent bacterial, viral, and fungal CC infections. Patients usually have chronic diarrhea, recurrent CC respiratory infections, and failure to thrive. Immunologic work-up CC shows a T-cell negative, B-cell positive, NK-cell positive phenotype. CC {ECO:0000269|PubMed:14602880, ECO:0000269|PubMed:15546002, CC ECO:0000269|PubMed:21883749}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- WEB RESOURCE: Name=CD3Dbase; Note=CD3D mutation db; CC URL="http://structure.bmc.lu.se/idbase/CD3Dbase/"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X03934; CAA27573.1; -; Genomic_DNA. DR EMBL; M12727; AAA51792.1; -; Genomic_DNA. DR EMBL; M12726; AAA51792.1; JOINED; Genomic_DNA. DR EMBL; CD014058; -; NOT_ANNOTATED_CDS; mRNA. DR EMBL; AP001582; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC039035; AAH39035.1; -; mRNA. DR EMBL; BC070321; AAH70321.1; -; mRNA. DR EMBL; X01451; CAA25683.1; -; Genomic_DNA. DR CCDS; CCDS41724.1; -. [P04234-2] DR CCDS; CCDS8394.1; -. [P04234-1] DR PIR; A94706; RWHUD1. DR RefSeq; NP_000723.1; NM_000732.4. [P04234-1] DR RefSeq; NP_001035741.1; NM_001040651.1. [P04234-2] DR RefSeq; XP_016874032.1; XM_017018543.1. DR PDB; 1XIW; X-ray; 1.90 A; B/F=23-100. DR PDB; 6JXR; EM; 3.70 A; d=1-171. DR PDB; 7FJD; EM; 3.20 A; d=1-171. DR PDB; 7FJE; EM; 3.00 A; d=1-171. DR PDB; 7FJF; EM; 3.10 A; d=1-171. DR PDB; 7PHR; EM; 3.08 A; D=22-132. DR PDB; 8ES7; EM; 3.04 A; D=1-171. DR PDB; 8ES8; EM; 2.65 A; D=1-171. DR PDB; 8ES9; EM; 3.25 A; D=1-171. DR PDBsum; 1XIW; -. DR PDBsum; 6JXR; -. DR PDBsum; 7FJD; -. DR PDBsum; 7FJE; -. DR PDBsum; 7FJF; -. DR PDBsum; 7PHR; -. DR PDBsum; 8ES7; -. DR PDBsum; 8ES8; -. DR PDBsum; 8ES9; -. DR AlphaFoldDB; P04234; -. DR EMDB; EMD-13427; -. DR EMDB; EMD-31618; -. DR EMDB; EMD-31619; -. DR EMDB; EMD-31620; -. DR EMDB; EMD-9895; -. DR SMR; P04234; -. DR BioGRID; 107353; 85. DR ComplexPortal; CPX-6482; Alpha-beta T cell receptor complex, TRBC2 variant. DR ComplexPortal; CPX-6581; Alpha-beta T cell receptor complex, TRBC1 variant. DR DIP; DIP-42855N; -. DR ELM; P04234; -. DR IntAct; P04234; 6. DR MINT; P04234; -. DR STRING; 9606.ENSP00000300692; -. DR ChEMBL; CHEMBL2364168; -. DR DrugBank; DB09052; Blinatumomab. DR DrugBank; DB00075; Muromonab. DR DrugBank; DB16684; Odronextamab. DR DrugBank; DB16655; Teclistamab. DR DrugCentral; P04234; -. DR GlyCosmos; P04234; 2 sites, No reported glycans. DR GlyGen; P04234; 2 sites. DR iPTMnet; P04234; -. DR PhosphoSitePlus; P04234; -. DR SwissPalm; P04234; -. DR BioMuta; CD3D; -. DR DMDM; 115985; -. DR jPOST; P04234; -. DR MassIVE; P04234; -. DR MaxQB; P04234; -. DR PaxDb; 9606-ENSP00000300692; -. DR PeptideAtlas; P04234; -. DR ProteomicsDB; 2194; -. DR ProteomicsDB; 51692; -. [P04234-1] DR ABCD; P04234; 1 sequenced antibody. DR Antibodypedia; 4581; 938 antibodies from 41 providers. DR DNASU; 915; -. DR Ensembl; ENST00000300692.9; ENSP00000300692.4; ENSG00000167286.11. [P04234-1] DR Ensembl; ENST00000392884.2; ENSP00000376622.2; ENSG00000167286.11. [P04234-2] DR GeneID; 915; -. DR KEGG; hsa:915; -. DR MANE-Select; ENST00000300692.9; ENSP00000300692.4; NM_000732.6; NP_000723.1. DR UCSC; uc001pss.2; human. [P04234-1] DR AGR; HGNC:1673; -. DR CTD; 915; -. DR DisGeNET; 915; -. DR GeneCards; CD3D; -. DR HGNC; HGNC:1673; CD3D. DR HPA; ENSG00000167286; Tissue enriched (lymphoid). DR MalaCards; CD3D; -. DR MIM; 186790; gene. DR MIM; 615617; phenotype. DR neXtProt; NX_P04234; -. DR OpenTargets; ENSG00000167286; -. DR Orphanet; 169160; T-B+ severe combined immunodeficiency due to CD3delta/CD3epsilon/CD3zeta. DR PharmGKB; PA26215; -. DR VEuPathDB; HostDB:ENSG00000167286; -. DR eggNOG; ENOG502S4XC; Eukaryota. DR GeneTree; ENSGT00940000153312; -. DR HOGENOM; CLU_115449_0_0_1; -. DR InParanoid; P04234; -. DR OMA; YQPLRDH; -. DR OrthoDB; 4266454at2759; -. DR PhylomeDB; P04234; -. DR TreeFam; TF335892; -. DR PathwayCommons; P04234; -. DR Reactome; R-HSA-198933; Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell. DR Reactome; R-HSA-202424; Downstream TCR signaling. DR Reactome; R-HSA-202427; Phosphorylation of CD3 and TCR zeta chains. DR Reactome; R-HSA-202430; Translocation of ZAP-70 to Immunological synapse. DR Reactome; R-HSA-202433; Generation of second messenger molecules. DR Reactome; R-HSA-389948; PD-1 signaling. DR Reactome; R-HSA-8856825; Cargo recognition for clathrin-mediated endocytosis. DR Reactome; R-HSA-8856828; Clathrin-mediated endocytosis. DR SignaLink; P04234; -. DR SIGNOR; P04234; -. DR BioGRID-ORCS; 915; 122 hits in 1160 CRISPR screens. DR ChiTaRS; CD3D; human. DR EvolutionaryTrace; P04234; -. DR GeneWiki; CD3D; -. DR GenomeRNAi; 915; -. DR Pharos; P04234; Tclin. DR PRO; PR:P04234; -. DR Proteomes; UP000005640; Chromosome 11. DR RNAct; P04234; Protein. DR Bgee; ENSG00000167286; Expressed in thymus and 163 other cell types or tissues. DR ExpressionAtlas; P04234; baseline and differential. DR GO; GO:0042105; C:alpha-beta T cell receptor complex; IDA:UniProtKB. DR GO; GO:0030669; C:clathrin-coated endocytic vesicle membrane; TAS:Reactome. DR GO; GO:0005737; C:cytoplasm; NAS:UniProtKB. DR GO; GO:0009897; C:external side of plasma membrane; IBA:GO_Central. DR GO; GO:0005886; C:plasma membrane; IDA:ComplexPortal. DR GO; GO:0042101; C:T cell receptor complex; IDA:MGI. DR GO; GO:0042802; F:identical protein binding; IDA:CAFA. DR GO; GO:0004888; F:transmembrane signaling receptor activity; IBA:GO_Central. DR GO; GO:0002250; P:adaptive immune response; NAS:ComplexPortal. DR GO; GO:0046631; P:alpha-beta T cell activation; NAS:ComplexPortal. DR GO; GO:0007166; P:cell surface receptor signaling pathway; IBA:GO_Central. DR GO; GO:0045059; P:positive thymic T cell selection; ISS:UniProtKB. DR GO; GO:0050852; P:T cell receptor signaling pathway; NAS:ComplexPortal. DR CDD; cd07691; IgC1_CD3_gamma_delta; 1. DR DisProt; DP00505; -. DR Gene3D; 2.60.40.10; Immunoglobulins; 1. DR Gene3D; 1.10.287.770; YojJ-like; 1. DR InterPro; IPR015484; CD3_esu/gsu/dsu. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR032052; Ig_4. DR InterPro; IPR003110; Phos_immunorcpt_sig_ITAM. DR PANTHER; PTHR10570:SF5; T-CELL SURFACE GLYCOPROTEIN CD3 DELTA CHAIN; 1. DR PANTHER; PTHR10570; T-CELL SURFACE GLYCOPROTEIN CD3 GAMMA CHAIN / DELTA CHAIN; 1. DR Pfam; PF16680; Ig_4; 1. DR Pfam; PF02189; ITAM; 1. DR SMART; SM00077; ITAM; 1. DR SUPFAM; SSF48726; Immunoglobulin; 1. DR PROSITE; PS51055; ITAM_1; 1. DR Genevisible; P04234; HS. PE 1: Evidence at protein level; KW 3D-structure; Adaptive immunity; Alternative splicing; Cell membrane; KW Direct protein sequencing; Disulfide bond; Glycoprotein; Immunity; KW Membrane; Phosphoprotein; Receptor; Reference proteome; SCID; Signal; KW Transmembrane; Transmembrane helix. FT SIGNAL 1..21 FT CHAIN 22..171 FT /note="T-cell surface glycoprotein CD3 delta chain" FT /id="PRO_0000016487" FT TOPO_DOM 22..105 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 106..126 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 127..171 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 138..166 FT /note="ITAM" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00379" FT MOD_RES 149 FT /note="Phosphotyrosine" FT /evidence="ECO:0007744|PubMed:12522270, FT ECO:0007744|PubMed:15144186" FT MOD_RES 160 FT /note="Phosphotyrosine" FT /evidence="ECO:0007744|PubMed:19690332" FT CARBOHYD 38 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 74 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 37..73 FT /evidence="ECO:0000269|PubMed:15534202" FT VAR_SEQ 92..136 FT /note="MCQSCVELDPATVAGIIVTDVIATLLLALGVFCFAGHETGRLSGA -> T FT (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15028279" FT /id="VSP_045800" FT VARIANT 147 FT /note="Q -> R (in dbSNP:rs45510201)" FT /id="VAR_049646" FT STRAND 26..29 FT /evidence="ECO:0007829|PDB:1XIW" FT STRAND 32..36 FT /evidence="ECO:0007829|PDB:1XIW" FT STRAND 41..46 FT /evidence="ECO:0007829|PDB:1XIW" FT STRAND 50..52 FT /evidence="ECO:0007829|PDB:1XIW" FT HELIX 53..55 FT /evidence="ECO:0007829|PDB:1XIW" FT STRAND 57..62 FT /evidence="ECO:0007829|PDB:1XIW" FT HELIX 63..65 FT /evidence="ECO:0007829|PDB:1XIW" FT STRAND 68..73 FT /evidence="ECO:0007829|PDB:1XIW" FT STRAND 76..78 FT /evidence="ECO:0007829|PDB:7PHR" FT HELIX 79..81 FT /evidence="ECO:0007829|PDB:7PHR" FT STRAND 84..91 FT /evidence="ECO:0007829|PDB:1XIW" FT STRAND 95..98 FT /evidence="ECO:0007829|PDB:7FJE" FT HELIX 103..122 FT /evidence="ECO:0007829|PDB:7FJE" FT TURN 123..127 FT /evidence="ECO:0007829|PDB:7FJE" SQ SEQUENCE 171 AA; 18930 MW; 6C1F248150186D21 CRC64; MEHSTFLSGL VLATLLSQVS PFKIPIEELE DRVFVNCNTS ITWVEGTVGT LLSDITRLDL GKRILDPRGI YRCNGTDIYK DKESTVQVHY RMCQSCVELD PATVAGIIVT DVIATLLLAL GVFCFAGHET GRLSGAADTQ ALLRNDQVYQ PLRDRDDAQY SHLGGNWARN K //